{
  "docId": "019de515-46e8-778b-9aa2-edc9d4857990",
  "docSlug": "9b80ae10198fa4f452f4044732defb94",
  "documentTitle": "MaxCyte | Investor Presentation Deck | 17 slides",
  "authorId": "maxcyte",
  "authorName": "MaxCyte",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 17,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de515-46e8-778b-9aa2-edc9d4857990/14",
  "deckHref": "/decks/019de515-46e8-778b-9aa2-edc9d4857990",
  "deckJsonHref": "/decks/019de515-46e8-778b-9aa2-edc9d4857990.json",
  "deckAnchorHref": "/decks/019de515-46e8-778b-9aa2-edc9d4857990#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.402,
        "w": 0.202,
        "x": 0.22,
        "y": 0.28
      },
      "kind": "image",
      "text": null,
      "attrs": {},
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "909d7b6e-5170-47ba-b6a6-fe7a81c9ec11",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.179,
        "x": 0.035,
        "y": 0.875
      },
      "kind": "image",
      "text": null,
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "64715e34-3603-42f3-aec8-5b45004699fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.276,
        "w": 0.219,
        "x": 0.676,
        "y": 0.207
      },
      "kind": "list",
      "text": "Gene-Editing Tools used in MaxCyte-Enabled Clinical Trials\nARCUS\nBase-editing (CRISPR)\nCRISPR\nRNA-Based Engineering\nTALENS\nZinc Finger Nucleases (ZFNs)",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25e6fbfe-c254-414c-84e6-0876b0641aa9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.602,
        "w": 0.602,
        "x": 0.035,
        "y": 0.184
      },
      "kind": "list",
      "text": "Indications in Active MaxCyte-Enabled Clinical Trials\nGenetic Diseases\nBeta-Thalassemia\nSickle Cell Disease\nChronic Granulomatous Disease (CGD)\nHematological Malignancies\nAcute Lymphoblastic Leukemia\nAcute Myeloid Leukemia\nChronic Lymphocytic Leukemia\nMultiple Myeloma\nNon-Hodgkin Lymphoma\nT-Cell Lymphoma\nInfectious Disease\nHIV\nSolid Tumors\nNon-small Cell Lung Cancer\nGlioblastoma\nRenal Cell Carcinoma\nOther Solid Tumors",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8692ed0c-7262-426a-917d-acbfbd20b83b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.21,
        "x": 0.699,
        "y": 0.69
      },
      "kind": "metric",
      "text": "2023/2024",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e0d73f4-916f-486e-accb-d5a4dbb9d8ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.159,
        "x": 0.275,
        "y": 0.69
      },
      "kind": "metric",
      "text": "1,000+",
      "attrs": {},
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e34d9d6-1705-4e9b-8c1a-08bde2b86b6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.29,
        "x": 0.659,
        "y": 0.579
      },
      "kind": "paragraph",
      "text": "First MaxCyte-Enabled Therapy is expected to be approved as early as",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3007b4ad-7368-4c1f-96e1-f41cfc4c17b4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.359,
        "x": 0.168,
        "y": 0.766
      },
      "kind": "paragraph",
      "text": "Estimated patients in active clinical trials enabled by MaxCyte",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc5c1b51-454a-4601-a5ba-d2a14d1666f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.013,
        "w": 0.44,
        "x": 0.035,
        "y": 0.83
      },
      "kind": "source-note",
      "text": "As of March 2023 / Includes Commercial and Academic Clinical Trials. Source: clinicaltrials.gov",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ca8a9a8-875f-4090-9228-0f1413baf739",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.013,
        "w": 0.12,
        "x": 0.744,
        "y": 0.819
      },
      "kind": "source-note",
      "text": "Source: Evaluate Pharma",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6606ec3-b4ba-45d6-92e9-46443fc0fbfd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.916,
        "x": 0.042,
        "y": 0.07
      },
      "kind": "title",
      "text": "MaxCyte Enables Next-Generation Cell Therapies Across a Variety of Diseases",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91f34f51-7818-43ac-ad2d-8c0595472a7a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "5d1de2db-2b1c-4e7a-a363-40459678ecd4",
      "evidence": "Indications in Active MaxCyte-Enabled Clinical Trials Genetic Diseases Beta-Thalassemia Sickle Cell Disease Chronic Granulomatous Disease (CGD) Hematological Malignancies",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}